Standards; Chiral Molecules; Enzyme Activators and Inhibitors; Pharmaceutical/API Drug Impurities/Metabolites;
(1R,2R)-Bortezomib is a diastereomer of Bortezomib (B675700), the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells. Targets the ubiquitin-proteasome pathway
400-821-0725
沪ICP备17019645号
